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Chronic pressure overload imposed by systemic hyper-tension is associated with an exaggerated deposition 
of collagen type I and III fibers in the interstitium and the 
perivascular region of the myocardium.1 Myocardial fibrosis 
impairs left ventricular (LV) function, thus facilitating the 
development of heart failure (HF) in hypertension.2 In this 
setting, it has been shown that, besides mechanical stress, 
several humoral factors are involved in the development of 
myocardial fibrosis.3
Cardiotrophin-1 (CT-1) is a member of the interleukin 6 
superfamiliy, which exerts its actions through its heterodi-
mer glycoprotein 130/leukemia inhibitory factor recep-
tor.4 CT-1 was originally characterized as a stress response 
factor inducing cardiomyocyte survival and protection 
in response to biomechanical stress.4 However, recent in 
vitro findings in rodent and canine cardiac fibroblasts5–7 
and vascular smooth muscle cells8 suggest that CT-1 also 
behaves as a profibrotic cytokine. In fact, in vivo studies 
performed in rats have shown that CT-1 induces fibrosis in 
different organs, including the heart.9,10 Although CT-1 has 
been shown to be increased in the myocardium of patients 
with HF,11,12 there are no available data on the mechanisms 
involved in its overproduction and its association with myo-
cardial fibrosis in HF.
Therefore, the aim of this study was to evaluate the potential 
associations of myocardial CT-1 with cardiomyocyte mechan-
ical stress at end diastole as assessed by the estimation of LV 
end-diastolic wall stress (LVEDWS)13 and collagen type I and 
III synthesis and deposition in hypertensive patients with HF. 
In addition, the association between circulating CT-1 and bio-
markers of myocardial fibrosis (carboxy-terminal propeptide 
of procollagen type I or PICP and amino-terminal propeptide 
of procollagen type III or PIIINP)14 was also studied in these 
patients. Finally, the ability of CT-1 to induce the activation of 
cultured human fibroblasts to myofibroblasts and to stimulate 
collagen synthesis was analyzed.
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Methods
Subjects
All subjects gave written informed consent to participate in the study, 
and the institutional review committee approved the study protocol. 
The study conformed to the principles of the Helsinki Declaration.
The population consisted of 31 patients with hypertension with a 
previous clinical diagnosis of chronic stage C HF. Patients were clas-
sified as having HF with preserved LV ejection fraction (HFPEF) or 
HF with reduced ejection fraction (HFREF) in accordance with the 
diagnostic criteria proposed by the European Society of Cardiology.15 
Three transvenous endomyocardial biopsies were taken from the 
middle area of the interventricular septum from each patient during a 
cardiac catheterization procedure. For further details on the inclusion 
and exclusion criteria and the clinical characteristics of the patients, 
see the online-only Data Supplement.
Septal endomyocardial biopsies were obtained from autopsies of 
7 age- and sex-matched subjects (5 men, 2 women; age, 58.33±5.41 
years) who died of noncardiovascular causes with no macroscopic 
and microscopic cardiac lesions. The presence of macroscopic ma-
lignancies or microscopic chronic kidney disease in the control group 
was excluded after review of their autopsy files. An additional group 
of 20 age- and sex-matched healthy subjects (16 men, 4 women; 
age, 59.15±3.48 years) was used as controls for biochemical studies. 
The presence of cardiovascular disease was excluded after a medical 
examination.
Cardiac Studies
Two-dimensional echocardiographic-Doppler and pulsed-Doppler 
imaging was performed in all of the patients. LV mass and dimen-
sions and mitral inflow parameters were measured. LVEDWS was 
calculated according to Iwanaga et al.16 To discard coronary artery 
disease (≥50% stenosis in a major epicardial coronary artery), cor-
onary arteriography was performed in all the patients. For further 
details, see the online-only Data Supplement.
Histomorphological and Immunohistochemical 
Studies
The fraction of myocardial volume with positive staining for col-
lagen (collagen volume fraction [CVF]) was determined by quan-
titative morphometry in sections stained with collagen-specific 
picrosirius red. The endocardium was excluded from the analysis. 
Immunohistochemical analysis of collagen types I and III was per-
formed on formalin-fixed and paraffin-embedded sections, and type I 
CVF and type III CVF were analyzed by quantitative morphometry.
Cellular localization of CT-1 was performed by immunohisto-
chemistry on formalin-fixed and paraffin-embedded sections. For 
further details, see the online-only Data Supplement.
Molecular Studies
Protein expression of collagen types I and III and CT-1 was analyzed 
in myocardial samples by Western blot, and data were expressed as 
arbitrary densitometric units relative to β-actin expression. The myo-
cardial expression of mRNA of CT-1 and α
1
 chain of procollagen 
types I and III was analyzed by reverse transcription real-time poly-
merase chain reaction, and data were expressed as arbitrary units rela-
tive to constitutive 18S ribosomal RNA. For further details, see the 
online-only Data Supplement.
Biochemical Determinations
Plasma CT-1 was measured by an in-house ELISA as previously 
reported.12 Serum PICP and plasma aldosterone were measured by 
radioimmunoassays (Orion Diagnostica and DiaSorin, respectively). 
Serum PIIINP and plasma amino-terminal propeptide of brain natri-
uretic peptide (NT-proBNP) were measured by ELISA (MyBioSource 
and Roche Diagnostics, respectively).
In Vitro Study
Adult human dermal fibroblasts (adult human dermal fibroblast line) 
and primary cell cultures of human cardiac fibroblasts were used 
(for further details, see the online-only Data Supplement). Dose–
response stimulation curves were performed with adult human der-
mal fibroblasts. Because procollagen type I and III mRNAs increased 
in a dose-dependent manner on CT-1 stimulation (Figure S1 in the 
online-only Data Supplement), a concentration of 10 ng/mL CT-1 
was selected for being the dose rendering a submaximal stimulation. 
A minimum of 7 independent experiments were performed for each 
condition. The expression of α-smooth muscle actin and procollagen 
type I and III mRNAs was analyzed by reverse transcription real-time 
polymerase chain reaction in unstimulated and CT-1–stimulated cells 
(for further details, see the online-online Data Supplement).
Statistical Analysis
The differences between 2 groups were analyzed with a Student t test 
for unpaired data once normality was demonstrated; otherwise, the 
Mann–Whitney U test was performed. The differences in qualitative 
variables were evaluated with a χ2 test. The correlation between con-
tinuously distributed variables was tested by correlation coefficients 
and univariate regression analysis. The influence of confounding 
factors on correlations was excluded by partial correlation analysis 
for quantitative parameters. Values are expressed as mean±SEM and 
categorical variables as numbers and percentages. A value of P<0.05 
was considered statistically significant.
Results
Clinical, Hormonal, and Cardiac Parameters
The clinical and hormonal characteristics of the patients are 
shown in Table S1. The group of patients was composed 
mainly of men, with overweight, most of them in New York 
Heart Association functional class III, who had been diag-
nosed of chronic HF for >2 years. All patients exhibited 
NT-proBNP levels >125 pg/mL, the cutoff value for chronic 
HF.17 Compared with control subjects, patients with HF pre-
sented elevated aldosterone levels (126.36±20.37 versus 
58.67±5.74 pg/mL; P<0.005). Whereas all patients were 
treated with a diuretic and either an angiotensin-converting 
enzyme inhibitor or an angiotensin receptor blocker, none of 
them was receiving treatment with mineralocorticoid recep-
tor antagonists. Table 1 and Table S2 show the echocardio-
graphic parameters of the whole population of patients and of 
Table 1. Cardiac Parameters in Patients With Heart Failure
Parameters Values 95% CI
LVMI, g/m2 160.87±9.61 141.24–180.50
LVEDD, mm 57.25±1.51 54.17–60.33
LVEDV, mL 166.29±10.36 145.13–187.47
LVEDVI, mL/m2 86.10±5.34 75.18–97.02
LVPWT, mm 9.64±0.23 9.16–10.11
IVST, mm 11.09±0.38 10.32–11.87
LVEF, % 46.13±2.83 40.34–51.91
PCWP, mm Hg 16.10±1.11 13.84–18.36
LVEDWS, Kdynes/cm2 30.01±1.98 25.95–34.06
Values are given as mean±SEM (n=31). CI indicates confidence interval; IVST, 
interventricular septum thickness; LVEDD, left ventricular end-diastolic diameter; 
LVEDV, left ventricular end-diastolic volume; LVEDVI, left ventricular end-diastolic 
volume index; LVEDWS, left ventricular end-diastolic wall stress; LVEF, left 
ventricular ejection fraction; LVMI, left ventricular mass index; LVPWT, left ven-
tricular posterior wall thickness; and PCWP, pulmonary capillary wedge pressure.
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the patients divided into 2 groups: those fulfilling criteria of 
HFPEF and those presenting with HFREF, respectively.
Myocardial and Plasma CT-1
The expression of both myocardial CT-1 mRNA and protein 
was higher (P<0.001) in the myocardium of patients with 
HF than in controls (Figure 1). In addition, plasma CT-1 was 
increased (P<0.001) in patients with HF compared with con-
trol subjects (Figure 1).
Myocardial CT-1 was localized mainly in cardiomyocytes 
but scarcely in other cell types (Figure 2). Whereas in controls 
CT-1 immunostaining was undetectable in 43% of subjects, 
mild in 28.5%, and moderate in 28.5%, in patients with HF 
its expression was mild in 36% of patients, moderate in 32%, 
and intense in 32% (P<0.005). Of note, CT-1 immunostaining 
seemed to be more intense in patients with HFREF than in 
patients with HFPEF (Figure 2). In fact, whereas in patients 
with HFREF CT-1 immunostaining was intense in 48% of 
patients, moderate in 26%, and mild in 26%, in patients with 
HFPERF its expression was intense only in 8% of patients, 
moderate in 42%, and mild in 50% (P<0.05). Furthermore, 
myocardial CT-1 protein was increased in patients with 
HFREF compared with patients with HFPEF (3.15±0.29 
versus 2.37±0.18 arbitrary densitometric units; P<0.05). 
Although the values for myocardial CT-1 mRNA and plasma 
CT-1 did tend to be higher in patients with HFREF than in 
patients with HFREF, the differences did not reach statistical 
significance (data not shown).
Myocardial Collagen
Total CVF was increased in patients with HF compared with 
control subjects (Figure S2; Table 2). All patients exhib-
ited total CVF values above the upper limit of normality in 
controls (95% confidence interval, 2.38%). Therefore, all 
patients with HF included in this study exhibited myocardial 
fibrosis. No differences in CVF were found between patients 
with HFPEF and HFREF. Compared with controls, patients 
with HF exhibited increased type I CVF and type III CVF 
(Figure S2; Table 2). In addition, increased expression of col-
lagen type I and III proteins was observed in patients with 
HF compared with controls (Table 2). Procollagen type I 
mRNA was increased, but procollagen type III mRNA was 
not significantly overexpressed in patients with HF compared 
with control subjects (Table 2). Of interest, collagen type III 
CVF (1.58±0.15 versus 0.96±0.16%; P<0.05) and protein 
(2.63±0.29 versus 1.55±0.28 arbitrary densitometric units; 
P<0.05) were increased in patients with HFREF compared 
with patients with HFPEF.
However, the serum levels of the biomarkers of myocardial 
fibrosis were increased (P<0.01) in patients with HF compared 
with control subjects (PICP: 139.93±6.17 versus 69.77±3.95 
μg/L; PIIINP: 477.07±78.45 versus 161.96±45.14 pg/mL).
Analysis of Associations
Myocardial CT-1 protein was correlated (P<0.05) with 
LVEDWS in patients with HF (Figure 3). In addition, myocar-
dial CT-1 protein was directly correlated (P<0.01 in all cases) 
with procollagen type I and III mRNAs and collagen type I 
and III proteins in all subjects (Figure 4). Of interest, all these 
correlations remained significant when we excluded the influ-
ence of several potential confounding factors (ie, age, sex, 
body mass index, estimated glomerular filtration rate, blood 
pressure, NT-proBNP, and aldosterone) in partial correlation 
analysis. No correlations were found between myocardial 
CT-1 mRNA and LVEDWS or collagen-related molecules.
Plasma CT-1 was directly correlated with serum PICP 
(r=0.550; P<0.001) and PIIINP (r=0.267; P<0.05) in all sub-
jects. In addition, circulating CT-1 was directly correlated 
with NT-proBNP (r=0.386; P<0.005) in all subjects. These 
correlations remained significant when we excluded the influ-
ence of several potential confounding factors (ie, age, sex, 
body mass index, estimated glomerular filtration rate, blood 
pressure, NT-proBNP, and aldosterone) in partial correlation 
analysis. No other correlations were found between myocar-
dial or plasma CT-1 and the remaining parameters measured 
in this study.
In Vitro Study
In both adult human dermal fibroblasts and freshly isolated 
human cardiac fibroblasts, stimulation with CT-1 increased 
α-smooth muscle actin mRNA compared with unstimulated 
cells (P<0.05 in both cases; Figure 5; Figure S3). Procollagen 
type I mRNA was increased in both cardiac (P<0.05) and 
dermal fibroblasts (P<0.001) exposed to CT-1 compared with 
control cells (Figure 5; Figure S3). Similarly, CT-1 stimulated 
procollagen type III mRNA (P<0.01) in both fibroblast types 
(Figure 5; Figure S3).
Figure 1. Myocardial expression of cardiotrophin-1 (CT-1) mRNA (A) and protein (B) in patients with heart failure (n=28 and n=31, 
respectively) and control subjects (n=7). C, Plasma CT-1 levels in patients with heart failure (n=31) and control subjects (n=20). Myocardial 
mRNA and protein data are corrected by 18s ribosomal mRNA and β-actin, respectively. ADU indicates arbitrary densitometric units; and 
AU, arbitrary units.
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Discussion
The main findings of this study are the following: (1) an excess 
of myocardial CT-1 protein is associated with LVEDWS and 
increased collagen type I and III mRNAs and protein expres-
sion in the fibrotic myocardium of hypertensive patients with 
HF, (2) an excess of plasma CT-1 is associated with increased 
levels of circulating biomarkers of myocardial fibrosis in 
hypertensive patients with HF, and (3) CT-1 induces human 
cardiac fibroblast differentiation to myofibroblasts and stimu-
lates procollagen type I and III expression in these cells.
Pathophysiological Aspects
Myocardial CT-1 was found to be abnormally overexpressed 
at mRNA and protein levels in patients with HF, thus con-
firming previous data showing an excess of CT-1 in the myo-
cardium of rats18,19 and humans12 with hypertension and HF. 
Based on the immunohistological localization, CT-1 seems to 
be localized mainly in cardiomyocytes from patients with HF. 
It has been previously shown that hypoxia,20 neurohumoral 
factors (eg, norepinephrine, angiotensin II, aldosterone),21–23 
and mechanical stretch24 stimulate CT-1 expression in car-
diomyocytes. In this regard, it must be noted that we ruled 
out the presence of coronary artery disease and microvascular 
ischemia in patients with HF. In addition, almost all patients 
from this study were treated with a β-blocker and either an 
 angiotensin-converting enzyme inhibitor or an angioten-
sin receptor blocker. Furthermore, no association was found 
between plasma aldosterone and myocardial CT-1. However, 
we found an association of LVEDWS with myocardial CT-1 
protein but not with mRNA, suggesting that increased dia-
stolic stretch might stimulate post-trancriptional mechanisms 
upregulating CT-1 in the myocardium of patients with HF, 
namely in those with HFREF.
CT-1 has been shown to stimulate overall protein and col-
lagen synthesis in cultured animal cardiac fibroblasts5,6,25 and 
vascular smooth muscle cells,8 as well as fibroblast growth 
and proliferation,6,25,26 through its receptor-triggered signal-
ing pathways. More recently, it has been reported that chronic 
administration of CT-1 to normotensive rats is associated with 
enhanced myocardial deposition of collagen type I and III 
fibers, increased LV volume, and reduced LV ejection frac-
tion.9 In addition, CT-1 knockout mice display lower arterial 
fibrosis than age-matched control animals.27 Collectively, 
these experimental data support a cardiovascular profibrotic 
role for CT-1.
Findings from the present study provide the first data sup-
porting also the potential profibrotic actions of CT-1 in the 
human heart. In fact, we found that myocardial CT-1 protein 
was associated with the expression of collagen type I and III 
proteins. Interestingly, we found that myocardial CT-1 pro-
tein was associated with the mRNA expression of procolla-
gen types I and III, pointing to a direct transcriptional effect 
of CT-1 on collagen production. The in vitro data showing 
that CT-1 increases the synthesis of procollagen type I and III 
mRNAs in human cardiac fibroblasts reinforce this possibility. 
In addition, we found that CT-1 stimulates the differentiation 
of human cardiac fibroblasts to myofibroblasts (as assessed by 
the increase in α-smooth muscle actin expression), which is in 
agreement with previous data showing that CT-1 induces myo-
fibroblast proliferation in rat cardiac fibroblasts.25,26 Therefore, 
CT-1 may contribute to the development of myocardial fibro-
sis in human HF by turning fibroblasts into myofibroblasts, 
which present a highly synthetic profibrotic phenotype.
Table 2. Myocardial Collagen Parameters in Control Subjects and Patients With Heart Failure
Parameters Control Subjects (n=7) Patients With HF (n=31) P Value
Total CVF, % 1.93±0.08 7.91±0.55 <0.001
Type I CVF, % 2.02±0.11 7.93±0.56 <0.001
Type III CVF, % 0.76±0.15 1.32±0.12 <0.005
Procollagen type I mRNA, AU 37.50±7.41 162.26±12.54 <0.001
Procollagen type III mRNA, AU 1.09±0.43 1.79±0.24 NS
Collagen type I protein, ADU 2.42±0.42 5.04±0.38 <0.005
Collagen type III protein, ADU 0.86±0.20 2.15±0.23 <0.05
Data for mRNA and protein are corrected by 18s ribosomal mRNA and β-actin, respectively. Values are given as mean±SEM. ADU indicates arbitrary 
densitometric units; AU, arbitrary units; CVF, collagen volume fraction; HF, heart failure; and NS, nonsignificant.
Figure 2. Immunostaining of cardiotrophin-1 (in 
brown) in histological sections of a myocardial 
specimen from 1 patient with heart failure 
and preserved left ventricular ejection fraction 
(HFPEF; A) and 1 patient with heart failure 
and reduced ejection fraction (HFREF; B; 
magnification ×400).
López et al  Cardiotrophin-1 and Myocardial Fibrosis  487
Myocardial fibrosis is known to contribute to LV diastolic 
and systolic dysfunction.2 In fact, it has been proposed that 
whereas an excess of collagen type I tissue may increase 
chamber stiffness and alter LV diastolic filling, an excess of 
collagen type III may interfere with the transduction of the 
force of cardiomyocyte contraction to the ventricular cham-
ber, thereby impairing LV ejection fraction.28 It thus can be 
hypothesized that the profibrotic effect of CT-1 may contrib-
ute to the deterioration of LV function in hypertensive patients 
with HF. This can be particularly relevant for patients with 
HFREF who exhibit both increased expression and deposition 
of collagen type III fibers and myocardial CT-1 protein expres-
sion compared with patients with HFPEF. This possibility 
does not exclude other mechanisms through which CT-1 may 
compromise cardiac function either directly altering cardio-
myocyte growth29 and contractility30 or indirectly increasing 
arterial stiffness.9
Clinical Aspects
In agreement with previous data,31 we found that plasma CT-1 
is abnormally increased in hypertensive patients with HF. It has 
been previously shown that the failing human heart secretes 
CT-1 via the coronary sinus into the peripheral circulation32,33; 
therefore, circulating CT-1 may reflect cardiac CT-1 release. 
Interestingly, we found an association between plasma CT-1 
and plasma NT-proBNP. Because circulating NT-proBNP is 
considered a biomarker of cardiomyocyte stress in patients 
with HF,34 it can be proposed that circulating CT-1 may also 
be a biomarker of the stressed cardiomyocyte in the hyperten-
sive failing human heart.
Plasma CT-1 was also associated with serum levels of PICP 
and PIIINP, both established biomarkers of myocardial fibro-
sis.14 In fact, it has been shown that serum PICP and PIIINP 
are directly correlated with the amount of collagen type I and 
III fibers, respectively, present in the myocardium of patients 
with HF.35,36 Therefore, our finding reinforces the link between 
CT-1 and myocardial fibrosis in hypertensive patients with HF 
and suggests that circulating CT-1 may be an additional bio-
marker of myocardial fibrosis in these patients.
Limitations
Several limitations need to be acknowledged. First, this was 
a study involving a relatively small number of patients. In 
Figure 3. Direct correlation between left ventricular end-diastolic 
wall stress (LVEDWS) and myocardial cardiotrophin-1 (CT-1) 
protein (y=0.049x+1.378) in patients with heart failure (n=29). 
CT-1 protein data are corrected by β-actin. ADU indicates 
arbitrary densitometric units.
Figure 4. Direct correlations 
between myocardial 
cardiotrophin-1 (CT-1) protein 
and procollagen type I mRNA 
(y=39.71x+42.25; n=28 patients 
and 7 controls; A) and collagen 
type I protein (y=0.918x+2.130; 
n=29 patients and 7 controls; B) 
in all subjects. Direct correlations 
between myocardial CT-1 
protein and procollagen type 
III mRNA (y=0.334x+0.303; 
n=28 patients and 7 controls; 
C) and collagen type III protein 
(y=0.557x+0.609; n=29 patients 
and 7 controls; D). Control 
subjects are represented by 
open circles and patients with 
heart failure by solid circles. 
These associations were 
maintained in the heart failure 
cohort: CT-1 protein and 
procollagen type I (r=0.405; 
P<0.05) and type III (r=0.516; 
P<0.01) mRNAs; CT-1 protein 
and collagen type I (r=0.406; 
P<0.05) and type III (r=0.411; 
P<0.05) proteins. mRNA and 
protein data are corrected 
by 18s ribosomal mRNA and 
β-actin, respectively. ADU 
indicates arbitrary densitometric 
units; and AU, arbitrary units.
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particular, the assessment of myocardial molecular param-
eters was performed on a limited number of biopsy samples. 
However, because of the nature of the goals under investiga-
tion, it was adequately powered. Second, we performed biop-
sies of the right side of the interventricular septum to assess 
the characteristics of collagen tissue. However, as we have 
shown previously,37 in terms of deposition of collagen fibers, 
the septum is representative of the free wall in the human 
hypertensive failing heart. Third, because of the methodology 
used for sample processing, the immunocytochemical analy-
sis of the intracellular localization of CT-1 expression within 
cardiomyocytes (eg, mitochondria, endoplasmic reticulum, 
intercalated disks) could not be performed. Fourth, because 
only patients with HF of hypertensive origin were included, 
caution is needed before the current observations are extrapo-
lated to the HF population at large.
Perspectives
This study shows for the first time that an excess of myocar-
dial CT-1 protein is associated with LVEDWS and fibrosis in 
hypertensive patients with HF. We also show for the first time 
that CT-1 stimulation induces myofibroblast differentiation 
and collagen synthesis in human cardiac fibroblasts. These 
data allow us to speculate that, in the failing hypertensive 
human heart, increased cardiomyocyte diastolic stress pro-
duces CT-1 as a protective mechanism, which in the long-term 
turns to be detrimental because it promotes fibrosis acting on 
cardiac fibroblasts. Therefore, CT-1 emerges as a candidate 
pathogenic factor of myocardial remodeling in patients with 
HF of hypertensive origin. Furthermore, our results set the 
stage for further studies aimed to explore the usefulness of 
CT-1 as both a diagnostic biomarker and a therapeutic tar-
get of cardiomyocyte stress and myocardial fibrosis in these 
patients.
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What Is New?
•	We report the associations of an excess of myocardial cardiotrophin-1 
(CT-1) protein with left ventricular end-diastolic wall stress and fibrosis 
in patients with heart failure (HF) of hypertensive origin. We also report 
the associations of circulating CT-1 with established circulating biomark-
ers of cardiomyocyte mechanical stress and myocardial fibrosis in pa-
tients with HF. Finally, we characterize the profibrotic activity of CT-1 on 
human cardiac fibroblasts.
What Is Relevant?
•	Up to now, CT-1 has been considered as a cardiomyocyte stress re-
sponse factor involved in long-term alterations of cardiomyocyte growth 
and function associated with HF in humans. Results from the current 
study suggest that the excessive production of this cytokine by the me-
chanically stressed cardiomyocyte may also be involved in the main 
alteration of the cardiac extracellular matrix present in human HF (ie, 
myocardial fibrosis). Therefore, our findings support the notion that CT-1 
is a major contributor to the global remodeling of the myocardium that 
occurs in the failing human hypertensive heart.
Summary
CT-1 emerges as a new potential pathogenic mediator, diagnos-
tic biomarker, and therapeutic target of cardiomyocyte stress and 
myocardial fibrosis in HF of hypertensive origin.
Novelty and Significance
